Market accessCompany release

Rhythm launches IMCIVREE in Japan for hypothalamic obesity and takes bivamelagon into Phase 3

🇺🇸 Rhythm Pharmaceuticals, Inc. (RYTM) · Tue 03 Nov 2026

Rhythm Pharmaceuticals' Q3 2026 update reports a Japanese launch on 13 October, US uptake after March approval, Phase 3 plans for bivamelagon and European reimbursement filings.

Rhythm Pharmaceuticals has begun the commercial launch of IMCIVREE (setmelanotide) in Japan for acquired hypothalamic obesity, according to its third-quarter 2026 earnings presentation. The company gave 13 October 2026 as the launch date.

In the US, the product was approved by the FDA on 19 March 2026. Rhythm reported more than 700 patient start forms so far, along with growing payer coverage.

The company also said it will move bivamelagon into Phase 3 trials in acquired hypothalamic obesity and Prader-Willi syndrome. This follows an amended licence agreement under which the royalty on bivamelagon falls to 1%.

In Europe, Rhythm said reimbursement dossiers have been submitted, ahead of launches planned for 2027. The summary does not specify which countries or agencies are involved, and further detail on timelines was not available.

What it means for your team

  • Market-access teams should note that European reimbursement dossiers for IMCIVREE are already filed, with launches targeted for 2027.
  • The Japanese launch adds a third major market for setmelanotide in acquired hypothalamic obesity, following US approval earlier this year.
  • Regulatory and clinical teams may want to watch for Phase 3 designs for bivamelagon in acquired hypothalamic obesity and Prader-Willi syndrome.
  • US payer coverage and patient start-form numbers offer an early indicator of uptake for a rare-disease launch.

Company's press release (SEC filing): Rhythm Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (Rhythm Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Market access All →